San Francisco, California
London, United Kingdom
The Bioscience Network Presents:
Biotech 2.1: Maximizing Shareholder Value by Understanding Your Options
Date & Location
May 1, 2014
Location: Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue, Boston, MA
So you got your company up and running and your therapeutic program is
rolling down the development pathway. You may even have been lucky enough
to have some positive early results. However, your current funding will
only get you so far. You need to think about what's next to maximize the
value that you have created. What will it be?
The public markets are open for business again, big pharma still has an
appetite for M&A to fill its pipeline, current investors may want to invest
more to build value or exit now to start harvesting some gains. As a
biotech leader, what are your options and how do you maximize the value to
satisfy your stakeholders?
Come listen to our panel of experts who have been there and hear insightful
advice, real life perspectives, exciting stories and possibly some sobering
news about the high risk world of biotech.
Marc Cote- COO of Accellient Partners, CFO of Synchroneuron Inc. and member
of Boston Harbor Angels
Walter Ogier- President and CEO, Acetylon Pharmaceuticals
Kush Parmar, MD, PhD- Partner, 5 AM Ventures
Jon A. Civitarese- Director of Investment Banking, Leerink Swann LLC
Jonathan P. Gertler, MD-Managing Partner and CEO, Back Bay Life Science Advisors
5:30-6:30pm: Cocktails, Hors d'oeuvres and Networking
6:30-8:00pm: Panel Discussion
The Bioscience Network (TBN)
Where you are the future of life sciences
TBN is a non-profit organization providing networking and professional growth to individuals in the Bioscience industries.